Dataset Information

N-terminal VP1 truncation favor T=1 norovirus-like particles

ABSTRACT: Noroviruses cause immense sporadic gastroenteritis outbreaks worldwide. Upcoming genotypes, which are divided based on VP1 sequence, further enhance this public thread regularly. Self-assembling properties of the human norovirus major capsid protein VP1 are crucial for using virus-like particles (VLPs) for vaccine development. However, there is no vaccine available yet. Here, VLPs from different variants produced in insect cells are characterized in detail using a set of biophysical and structural tools.

INSTRUMENT(S): Orbitrap Fusion, Q Exactive

ORGANISM(S): Norovirus

SUBMITTER: Christoph Krisp

LAB HEAD: Dr Charlotte Uetrecht

PROVIDER: PXD023182 | Pride | 2021-01-11

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	02_100pmolSaitamaVLP_mapping34min.mzML	Mzml
	02_100pmolSaitamaVLP_mapping34min.raw	Raw
	04_100pmolWestChesterVLP_prep2_mapping34min.mzML	Mzml
	04_100pmolWestChesterVLP_prep2_mapping34min.raw	Raw
	07_100pmol_GII10Vietnam_VLP_mapping.mzML	Mzml

Items per page:

1 - 5 of 41

Publications

N-terminal VP1 Truncations Favor <i>T</i> = 1 Norovirus-Like Particles.

Pogan Ronja R Weiss Victor U VU Bond Kevin K Dülfer Jasmin J Krisp Christoph C Lyktey Nicholas N Müller-Guhl Jürgen J Zoratto Samuele S Allmaier Günter G Jarrold Martin F MF Muñoz-Fontela Cesar C Schlüter Hartmut H Uetrecht Charlotte C

Vaccines 20201224 1

Noroviruses cause immense sporadic gastroenteritis outbreaks worldwide. Emerging genotypes, which are divided based on the sequence of the major capsid protein VP1, further enhance this public threat. Self-assembling properties of the human norovirus major capsid protein VP1 are crucial for using virus-like particles (VLPs) for vaccine development. However, there is no vaccine available yet. Here, VLPs from different variants produced in insect cells were characterized in detail using a set of b ...[more]

PMID: 33374273

Similar Datasets

Project description:Human papilloma (HPV) virus-like particle (VLP) vaccines were recently licensed. Though neutralizing antibody titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet defined and a comprehensive understanding of innate and adaptive immune responses to vaccination is still lacking. Here, microarrays were used to compare the gene expression signature in HPV-16 L1 VLP-stimulated PBMC from 17 vaccine and 4 placebo recipients before vaccination, and 1 month after receiving the second immunization. Vaccination with HPV-16 L1 VLP was associated with modulation of genes involved in the inflammatory/defense response, cytokine, interferon and cell cycle pathways in VLP-stimulated PBMC. In addition, there was up-regulation of probesets associated with cytotoxic (GZMB, TNFSF10) and regulatory (INDO, CTLA4) activities. The strongest correlations with neutralizing antibody titers were found for cyclin d2 (CCND2) and galectin (LGALS2). Twenty-two differentially expressed probesets were selected for confirmation by RT-PCR in an independent sample set. Agreement with the microarray data was seen for over two-thirds of these probesets. Up-regulation of immune/defense response genes by VLP, in particular interferon-induced genes was observed in PBMC collected prior to vaccination, with many of these genes being further induced following vaccination. In conclusion, we used gene expression profiling to identify important innate and adaptive response related- genes induced by vaccination with HPV VLP. Further studies are needed to identify gene expression signatures of immunogenicity and long-term protection with potential utility in prediction of long-term HPV vaccination outcomes in clinical trials. Experiment Overall Design: Microarrays (Affymetrix Human Focus) were used to compare the gene expression signature in PBMCs stimulated for 3 days with media alone, Sf9/baculovirus insect cell lysate, and HPV-16 L1 VLP expressed from baculovirus-infected Sf9 insect cells from 17 vaccine and 4 placebo recipients before vaccination, and 1 month after receiving the second immunization (2 months after the initial immunization. Post-vaccination baculovirus sample for Pt078 and pre-vaccination baculovirus sample for Pt082 failed QC.